| Indication |
For the treatment of functional bowel/irritable bowel syndrome
including Colicky abdominal pain; diverticulitis |
| Pharmacodynamics |
Dicyclomine is an anticholinergic drug, a medication that
reduces the effect of acetylcholine, a chemical released from nerves
that stimulates muscles, by blocking the receptors for acetylcholine on
smooth muscle (a type of muscle). It also has a direct relaxing effect
on smooth muscle. Dicyclomine is used to treat or prevent spasm in the
muscles of the gastrointestinal tract in the irritable bowel syndrome.
In addition, Dicyclomine inhibits gastrointestinal propulsive motility
and decreases gastric acid secretion and controls excessive pharyngeal,
tracheal and bronchial secretions. |
| Mechanism of action |
Action is achieved via a dual mechanism: (1) a specific
anticholinergic effect (antimuscarinic) at the acetylcholine-receptor
sites and (2) a direct effect upon smooth muscle (musculotropic). |
| Absorption |
Not Available |
| Volume of distribution |
- 3.65 L/kg [20 mg oral dose]
|
| Protein binding |
>99% |
| Metabolism |
Not Available |
| Route of elimination |
The principal route of elimination is via the urine (79.5% of the
dose). Excretion also occurs in the feces, but to a lesser extent
(8.4%). |
| Half life |
Not Available |
| Clearance |
Not Available |
| Toxicity |
Not Available |
Comments
Post a Comment